Novo Holdings Curbs Funding by Billions Amid Political Turmoil

Novo Holdings A/S, the investment vehicle that controls Novo Nordisk A/S, is investing billions less in new life science companies, exercising caution because of geopolitical uncertainty and technology disruptions.

“We’re right in the heart of a pretty opaque period right now in many ways,” Chief Executive Officer Kasim Kutay said in an interview. The restraint will last “until we feel that we have better answers to some of the key due diligence questions that we’re asking today that we actually weren’t asking just two, three years ago.”